Movianto’s Active Frozen Transport for Vaccine Campaigns

Movianto, a key player in healthcare logistics since joining the Walden Group in 2020, has positioned itself as a premier European partner for pharmaceutical and healthcare industries. The company specialises in handling pharmaceutical and biotech products, medical devices and diagnostics, offering comprehensive logistics solutions tailored to the healthcare sector.

Movianto scales up vaccine logistics with -25°C frozen transport

As a crucial link in the healthcare supply chain, Movianto provides temperature-controlled warehouse logistics and transport services, alongside integrated solutions such as order-to-cash and procurement services, all essential for maintaining the integrity of sensitive medical products.

In a significant development for the UK healthcare system, Movianto has expanded its capabilities to support the 2024/2025 autumn vaccine and flu campaigns. This expansion marks a milestone for the company, introducing active frozen transport solutions that can maintain temperatures as low as -25°C for vaccines and critical medicines.

“Building on long-established partnerships and supply chain relationships as fleet and industry experts, we’ve introduced additional capability to support our key contracts in facilitating active frozen distribution and delivery of COVID-19 and seasonal flu vaccines to the UK healthcare system and NHS end users,” said Ben Williams, Account Director for Government Contracts at Movianto UK. “This is significantly reducing costs, improving delivery lead times and creating a more agile solution.”

Movianto's expertise in vaccine and medicine logistics within the UK healthcare market spans various temperature ranges, including ambient, controlled ambient, chilled and frozen conditions. The company's latest innovation addresses the challenges of traditional -25°C vaccine distribution, which typically relies on costly and time-sensitive passive shippers and dry ice. 

In preparation for the autumn healthcare campaign, Movianto has adapted its existing fleet and trailers to operate at -25°C, enhancing its ability to transport and store frozen medical cargo efficiently.

Movianto enhances vaccine transport efficiency with direct loading and temperature-controlled warehouses

“Our teammates no longer need to specially prepare and pack vaccines into shippers with dry ice,” says David Evans, Managing Director at Movianto UK. “Instead, they can load the goods straight onto the trailers which can dock directly into our temperature-controlled warehouse facilities.

“The additional capability of active frozen vaccine transport is a good example of how logistics chains – even for the same products – can evolve, become more efficient and meet the needs of clients. 

“This is exactly why we’ve continuously developed and optimised our methods and supply chains. If this requires investment, we’re willing and able to partner with clients to implement tailored solutions.”

The Walden Group, Movianto's parent company, is at the forefront of healthcare supply chain solutions in Europe. It offers comprehensive services across the pharmaceutical supply chain, including specialised logistics, value-added services, and innovative solutions crucial for modern healthcare delivery.

With its strategic growth, the Walden Group now operates in 15 countries, employing around 6,000 people across more than 250 sites, reinforcing its commitment to advancing healthcare logistics and supporting global health initiatives.

Global vaccine manufacturing challenges

Vaccine accessibility should be a human right, but sadly, it is not. The African subcontinent highlights this inequality, as while making up 20% of the global population, its vaccine industry contributes less than 1% to the worldwide provision. 

Over 99% of vaccines are imported into the continent, making African nations reliant on external support. COVID-19 underlined the lack of vaccine production and health technologies based in Africa. This dependence slowed the vaccination process across Africa, compared to regions like Europe and the US, leading to wider spread and more deaths that could have been prevented.

Moderna announced the construction of a US$500m mRNA vaccine production facility in Kenya, which will focus on producing vaccines that can be quickly adapted to combat various diseases. This project aims to produce 500m vaccine doses each year.

Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Healthcare LIVE 2025

Healthcare Digital is a BizClik brand